Furthermore, a wealth of preclinical data demonstrate the effectiveness of receptor tyrosine kinase inhibitors and neutralizing antibody against MM cells expressing FGFR3-activating mutations and wild-type receptor (reviewed in [3]–[5]). Here, FGFR3 is linked to Miyoshi myopathy.